Boothbay Fund Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Boothbay Fund Management’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-796	Closed	-$9.39K	–	2561
2023 Q1	$9.39K	Hold	796	–	–	﹤0.01%	2075
2022 Q4	$11.5K	Hold	796	–	–	﹤0.01%	1936
2022 Q3	$40K	Sell	796 -578	-42%	-$40.2K	﹤0.01%	2130
2022 Q2	$117K	Buy	1,374 +306	+29%	+$26.2K	﹤0.01%	1946
2022 Q1	$161K	Hold	1,068	–	–	﹤0.01%	1964
2021 Q4	$319K	Hold	1,068	–	–	0.01%	1230
2021 Q3	$416K	Sell	1,068 -117	-10%	-$49.9K	0.01%	1173
2021 Q2	$500K	Buy	1,185 +599	+102%	+$259K	0.02%	1004
2021 Q1	$284K	Buy	+586	New	+$298K	0.01%	1219

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Boothbay Fund Management's FNCH Position: Q2 2023 in Review

Boothbay Fund Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 796 shares — an estimated $9.39K sold.

Boothbay Fund Management first reported a position in FNCH in Q1 2021 and held it in 9 quarters. The position peaked at $500K in Q2 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

Boothbay Fund Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 796 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $9.39K.
Boothbay Fund Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Boothbay Fund Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $500K in Q2 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.